Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Gastroenterol (2014) 146:66980
Need urgent medical intervention: If you have severe obesity with acute complications requiring immediate medical management, hospital-based weight loss surgery evaluation, or intensive medical supervision, telehealth GLP-1 platforms are not a substitute for urgent in-person care
[12] [13] Stop taking semaglutide and consult your doctor immediately if you suspect these conditions
The body can also experience skin laxity, stubborn fat pockets, and diminished tone
Take home message In Phase 3 trials, retatrutide has produced higher weight loss than Wegovy: 28.7% at 68 weeks on the 12 mg dose, compared with 20.7% at 72 weeks on the newer Wegovy 7.2 mg dose, and 14.9% at 68 weeks on the older 2.4 mg dose
Victoza (active ingredient:liraglutide) subcutaneous injection Initial FDA Approval: 2010 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
